MELANOMA

This early-phase study tested a personalized vaccine made from each patient's unique melanoma mutations. The goal was to see if the vaccine could be made safely and trigger a strong immune response to help prevent the cancer from coming back. Fifteen people with advanced melanoma…

This early-phase study tested a new vaccine called WDVAX in 23 people with advanced melanoma. The vaccine is made from each patient's own killed tumor cells, combined with immune-boosting proteins, and formed into a small tablet. The goal was to see if it's safe and possible to c…

This early-phase study tested a new RNA-based cancer vaccine in 119 people with advanced melanoma. The vaccine targets four proteins found on melanoma cells to train the immune system to fight the cancer. The main goal was to check safety and find the right dose, with early signs…

This study tested several experimental drug combinations in people with stage III melanoma that could be surgically removed. The goal was to see if adding a new drug to the standard immunotherapy pembrolizumab could improve tumor clearance before surgery. About 146 participants r…

This study tested whether a combination of two targeted drugs (LGX818 and MEK162) works better than standard treatments for people with advanced melanoma that has a specific BRAF gene change. About 900 patients took part. The goal was to see if the combo could slow cancer growth …

This early-phase study tested a new treatment called VE800, made from live bacteria, combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goals were to check safety and see if tumor…

This study tested a new treatment for people with advanced melanoma that can be removed by surgery. The treatment combined an injected gene therapy (Tavo) with an intravenous immunotherapy drug (nivolumab) given before and after surgery. The goal was to see if this approach could…

This study tested a new drug (E7386) combined with an immunotherapy (pembrolizumab) in 89 people with advanced melanoma, colorectal, or liver cancer who had already tried other treatments. The goal was to check safety and see if the combination shrinks tumors. Results help decide…

This early-stage study tested a new drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced cancers like lung cancer, melanoma, or head and neck cancer that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal…

This early-phase study tested a combination of two drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had not responded to previous treatments. The main goal was to find the safest dose and see if the combination could shrink tumors. While not a cure, the a…

This study tested a new treatment for people with advanced melanoma that cannot be removed by surgery. The treatment uses a virus to deliver a gene that makes a protein called IL-12, which helps the immune system attack cancer cells. Patients also took an oral drug to control the…

This study tested a new drug, ABP 206, to see if it works as well as the approved drug OPDIVO for people with advanced melanoma that has been removed by surgery. The trial involved 256 adults who had their melanoma completely removed within the last 12 weeks. The goal was to comp…

This study tested a new treatment called lerapolturev, a modified polio virus, alone or combined with an immunotherapy drug, in 27 adults with advanced melanoma that no longer responded to PD-1 inhibitors. The goal was to see if the virus could shrink tumors or improve survival. …

This study tested two doses of an experimental drug called RO7247669 in 93 people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if the drug could control the cancer and help people live longer without it getting worse. Researchers …

This early-phase trial tested a drug called MEDI0562, which aims to boost the immune system's ability to fight cancer. It was given to 13 patients with advanced head and neck cancer or melanoma before their surgery. The main goal was to see if the drug safely activates the immune…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 participants took part. The goal was to see how many patients had their tumors…

This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific genetic change (KIT mutation) and cannot be removed by surgery. The main goals were to see if the drug is safe and whether it can shrink tumors. The study was …

This study looked at 216 people with advanced melanoma that didn't have common BRAF or NRAS mutations and had stopped responding to standard therapy. Researchers analyzed each person's tumor DNA to find specific mutations and then gave them a drug designed to target that mutation…

This study tested whether taking two targeted drugs (dabrafenib and trametinib) for 12 months after melanoma surgery could prevent the cancer from coming back. It involved 870 adults with high-risk stage III melanoma that had a specific BRAF V600 mutation. Participants were rando…

This study tested an experimental drug called BMS-986253 combined with two immunotherapy drugs (nivolumab and ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if the tumors shrank. This is a disease control approach, not a…

This early-stage study tested a new drug, CCT3833, in 31 adults with advanced solid tumors, including melanoma. The main goal was to find a safe dose and understand side effects. Researchers also looked at how the drug moves through the body. This is not a cure, but a step toward…

This study tested a combination of three immune-boosting drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma. 25 adults with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if denos…

This study tested experimental drug combinations for people with advanced melanoma that has spread to the brain. It included 56 participants who had not been treated with certain immune therapies or had already received them. The goal was to see if the new combinations were safer…

This early-stage study tested a new treatment for people with advanced bladder, skin (melanoma), or head and neck cancers. Doctors took patients' own immune cells, modified them in a lab to better recognize and attack cancer cells, and then infused them back. The main goal was to…

This early-phase study tested a personalized vaccine made from yeast that is designed to teach the immune system to recognize and attack leftover cancer cells. It included 5 adults with different cancers who had already completed treatment aimed at curing their disease. The goal …

This early-phase study tested a new drug called BAT4706 in 28 people with advanced solid tumors (including melanoma) who had no other good treatment options. The main goal was to check the drug's safety and find the best dose for future studies. This is not a cure, but a step tow…

This early-phase study tested whether adding a TNF-blocker (infliximab or certolizumab) to standard immunotherapy (nivolumab + ipilimumab) is safe for people with advanced melanoma that has spread or cannot be removed. 33 adults aged 18–70 took part. The main goal was to find the…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination improved the time withou…

This early-phase trial tested whether combining a special type of radiation (hypofractionated radiotherapy) with two immunotherapy drugs (MEDI4736 and tremelimumab) is safe and tolerable for people with advanced melanoma, lung, breast, or pancreatic cancer that has spread. The st…

This study tested a new treatment called GC101 TIL for people with advanced melanoma that did not respond to standard therapies. The treatment uses a patient's own immune cells, grown in a lab, to fight the cancer. The goal was to check safety and see if tumors shrink. 18 patient…

This early-stage study tested a new drug called CFT1946 in 89 adults with advanced solid tumors that have a specific BRAF V600 gene change. The goal was to find safe doses and see if the drug, given alone or with other medicines, can shrink tumors. The study focused on safety and…

This study tested a new type of stem cell transplant for children and young adults (ages 2-21) with cancers that came back or didn't respond to treatment. The approach uses a special cell filter to speed up immune recovery after transplant. The main goal was to see if the procedu…

This study tested a new drug combination for people with advanced melanoma that had stopped responding to standard immunotherapy. The treatment involved injecting BO-112 directly into tumors along with pembrolizumab given through a vein. The goal was to see if the combination cou…

This study tested a computer system that uses artificial intelligence (AI) to spot skin cancer (melanoma) from photos of skin spots. 105 adults with suspicious moles participated. Researchers compared the AI's accuracy to expert dermatologists and lab biopsy results. The goal is …

This study tested a breath analysis device (eNose) to see if it can predict which cancer patients will benefit from immunotherapy. Researchers collected breath samples from 190 adults with lung, melanoma, bladder, kidney, or head and neck cancers before treatment. The goal was to…

This study tested whether a new blood test (liquid biopsy) can accurately find cancer biomarkers in patients with head and neck, lung, or skin cancer. 135 adults with advanced cancer provided blood and tumor tissue samples. The goal was to see if the blood test works as well as t…

This study looked at whether giving a written sheet to melanoma patients, to pass on to their close relatives, helps those relatives see a doctor for a skin exam. About 420 patients and their relatives took part. The goal was to see if the written reminder works better than just …

This study tested a sun safety program for high school students in rural Utah. The program included in-class lessons and was designed to be easy for schools to continue on their own. Researchers surveyed 38 students before and after the program to see if they improved their sun p…

This study looked at whether smelling lavender essential oil for 15 minutes before surgery could reduce anxiety in people having skin cancer removed. 66 adults took part, and researchers measured their anxiety levels using questionnaires and vital signs. The goal was to see if th…

This small pilot study looked at whether special PET scans and blood tests can help predict how well melanoma patients respond to immunotherapy drugs like nivolumab or pembrolizumab. Five people with advanced melanoma took part. Researchers collected scans, blood samples, and tum…

This study examined blood and tumor samples from 25 people with advanced melanoma to understand why some respond to the immunotherapy drug pembrolizumab while others do not. Researchers analyzed T cells—key immune cells—to find genetic and behavioral clues that predict treatment …

This study looked at how people with a close family history of melanoma make choices about sun protection, like using sunscreen or seeking shade. Researchers interviewed 94 participants to understand the reasons behind these decisions. The goal is to use this knowledge to better …

This study followed 187 melanoma patients treated with IMLYGIC, a virus-based therapy, to see if the virus spreads to close contacts or healthcare workers. Researchers also checked for long-term safety issues over 5 years. The goal was to understand real-world risks, not to test …

This study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient characteristics, treatment pat…

This study examined whether melanoma cells can lie dormant in healthy tissue near a tumor and whether their presence affects long-term survival. Researchers followed 226 adults with early-stage melanoma for 5 years, checking for these hidden cells and tracking survival and recurr…

This study set up a platform to deeply analyze tumors from 116 people with advanced melanoma. Researchers collected tumor biopsies, blood, and stool samples to create detailed molecular reports. The goal was to find new patterns in tumor biology that could help doctors choose bet…

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs (either a single drug or a combination). Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for markers that might…

This study looked at whether a new biomarker called 'mass response' can help predict how well cancer treatments will work. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or biopsies. The goal was to see if this biomarker could guide ther…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…

This study looked at immune cells (T cells, NK cells, and macrophages) inside melanoma tumors from 217 patients. Researchers wanted to understand how these cells affect the body's ability to fight the cancer and how chemotherapy might change them. The goal was to learn more about…

This study looked at how inflammation changes in the blood of people receiving immunotherapy for cancer. Researchers measured inflammatory markers to understand and possibly predict side effects. 98 adults with cancers like melanoma or lung cancer took part. The goal was to gathe…

This study looked at whether a blood test that measures tumor DNA (ctDNA) can help predict if melanoma will come back or get worse. Researchers followed 113 adults with melanoma, taking blood samples and checking their medical records. The goal was to see if ctDNA levels match kn…

This study tested a new way for patients to share their family health history with their doctor using an app. The goal was to see if this helps doctors spot people at higher risk for certain cancers, heart disease, or diabetes. Over 600 adults aged 30-69 took part. The approach i…

This study observed 39 patients in Turkey who had high-risk stage III melanoma removed by surgery and were then treated with dabrafenib and trametinib. Researchers tracked how long patients stayed cancer-free and how long they took the medication. The goal was to see how well the…